---
schema_version: "secwatch.filing_event.v1"
accession: "0001789769-24-000082"
form_type: "8-K"
ticker: "TIL"
cik: "0001789769"
company_name: "Instil Bio, Inc."
filed_at: "2024-08-13T23:59:59+00:00"
generated_at: "2026-05-31T09:46:13.412426+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Instil Bio Q2 net loss $2.29/share; in-licenses two assets, leases facility to AstraZeneca

## Summary
- Net loss per share $2.29 (GAAP), non-GAAP $1.57 for Q2 2024; improved from $2.87 and $2.03 in Q2 2023.
- Cash, equivalents, marketable securities and long-term investments $152.6M as of June 30, expected runway beyond 2026.
- In-licensed SYN-2510 (PD-L1xVEGF bispecific) and SYN-27M (ADCC-enhanced anti-CTLA-4) from ImmuneOnco for exclusive global rights outside Greater China.
- Executed 15-year lease of cell therapy manufacturing facility to AstraZeneca; initial base rent >$7.5M annually escalating at 3%.
- R&D expenses fell to $2.9M in Q2 2024 from $8.5M in Q2 2023; restructuring and impairment charges minimal.

## SEC filing metadata
- accession: 0001789769-24-000082
- form_type: 8-K
- ticker: TIL
- cik: 0001789769
- company_name: Instil Bio, Inc.
- filed_at: 2024-08-13T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1789769/000178976924000082/0001789769-24-000082-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1789769/000178976924000082/til-20240813.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001789769-24-000082
- JSON: https://secwatch.observer/filing/0001789769-24-000082.json
- Plain text: https://secwatch.observer/filing/0001789769-24-000082.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.